Revolution Medicines Presents RAS(ON) Data at ESMO 2026
REDWOOD CITY, Calif., June 24, 2026 Revolution Medicines announced that new clinical data from its innovative RAS(ON) inhibitor portfolio...
AI drug discovery AI healthcare artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
REDWOOD CITY, Calif., June 24, 2026 Revolution Medicines announced that new clinical data from its innovative RAS(ON) inhibitor portfolio...
REDWOOD CITY, Calif., April 19, 2026 A major breakthrough in targeted oncology therapy has emerged as Revolution Medicines unveiled...
